# GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

> **NCT00480025** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 2278 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **BIOLOGICAL:** GSK1572932A Antigen-Specific Cancer Immunotherapeutic
- **BIOLOGICAL:** Placebo Control

## Key facts

- **NCT ID:** NCT00480025
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10-04
- **Primary completion:** 2013-12-06
- **Final completion:** 2014-09-23
- **Target enrollment:** 2278 (ACTUAL)
- **Why stopped:** The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480025, "GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00480025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*